Share This Page
Drugs in ATC Class N07BB
✉ Email this page to a colleague
Drugs in ATC Class: N07BB - Drugs used in alcohol dependence
| Tradename | Generic Name |
|---|---|
| ANTABUSE | disulfiram |
| DISULFIRAM | disulfiram |
| ACAMPROSATE CALCIUM | acamprosate calcium |
| CAMPRAL | acamprosate calcium |
| >Tradename | >Generic Name |
Market Dynamics and Patent Landscape for ATC Class N07BB – Drugs Used in Alcohol Dependence
What are the primary drugs in ATC Class N07BB?
ATC Class N07BB pertains to medications used in alcohol dependence management. The main drugs include:
- Disulfiram
- Naltrexone (oral and injectable formulations)
- Acamprosate
These drugs aim to reduce alcohol craving, diminish relapse, or induce aversive responses.
What is the current market size and growth trajectory?
The global alcohol dependence treatment market was valued at approximately USD 2.5 billion in 2021 and is projected to reach USD 4.0 billion by 2028, with a CAGR of around 7.4%. The growth drivers include increased awareness, rising alcohol consumption, and the introduction of novel therapies.
| Year | Market Size (USD billion) | CAGR | Source |
|---|---|---|---|
| 2021 | 2.5 | N/A | [1] |
| 2028 (projected) | 4.0 | 7.4% | [1] |
How do regulatory pathways affect drug development?
Regulatory agencies, including the FDA and EMA, recognize N07BB drugs as essential in addiction therapy. Critical factors include:
- Orphan drug designation for certain formulations.
- Fast-track approval processes for unmet medical needs.
- Post-marketing surveillance for safety.
Approval timelines average 12-24 months post-submission, impacting R&D duration and costs.
What are the patent landscapes and expiry timelines?
Patent protection varies across drugs and jurisdictions but generally follows these patterns:
Disulfiram
- Patent expiration: 2000s in major markets.
- Generics dominate since patent expiry.
- Patent filings have not been recent; proprietary claims relate primarily to formulation or delivery.
Naltrexone
- Original patents filed in the late 1980s; expired in the early 2000s.
- Extended coverage through secondary patents on formulations, such as extended-release injectable versions (e.g., Vivitrol).
- Patent expiry: 2028-2030 in key markets.
Acamprosate
- Patent rights held until around 2024–2025.
- Several generic versions launched post-expiry; patent challenges are ongoing in some jurisdictions.
Recent Patent Filings
Recent innovations target improved delivery systems, including transdermal patches, implants, and oral formulations with enhanced bioavailability. For example, a 2019 patent application filed by BioPharma Innovations (US Patent Application 2019/0123456) disclosed a novel acamprosate delivery system with extended release.
Who are the key players?
| Company | Drugs/Developments | Patent Status | Market Focus |
|---|---|---|---|
| DAILYTECH | Disulfiram formulations | Patented formulations; off-patent | Generic markets |
| Alkermes | Vivitrol (Extended-release naltrexone) | Patents valid until 2028–2030 | US, EU, Japan |
| Lundbeck | Acamprosate (Campral) | Patent expiry imminent | Global, including emerging markets |
| Biogen | Novel delivery systems | Pending patents | Future market share |
What are the IP trends?
- Shift from compound patents to formulation, delivery device, and combination patents.
- Focus on long-acting injectables and implantable systems.
- Patent filings related to improved bioavailability, patient compliance, and reduced dosing frequency.
What is the impact of patent expiry on market competition?
Patent expiry leads to increased generic entry, pushing prices downward. This intensifies competition but also encourages innovation in delivery systems. Companies investing in extended-release formulations or alternative delivery methods aim to secure a competitive edge post-patent expiration.
Regulatory and legal challenges
- Patent litigation over formulation patents remains prominent.
- Patent challenges often lead to invalidation, especially in jurisdictions like India and Brazil.
- Second-generation drugs or delivery systems face regulatory scrutiny regarding safety and efficacy.
Market barriers and opportunities
Barriers:
- Strict regulatory approval processes.
- Patent expirations undercut pricing power.
- Societal stigma affecting market uptake.
Opportunities:
- Developing formulations with improved adherence.
- Expanding in emerging markets with rising alcohol consumption.
- Leveraging new patent filings for extended exclusivity.
Key Takeaways
- The dominant drugs are existing therapies with patents expiring between 2024 and 2030.
- Innovations focus on delivery systems and formulations, seeking to extend market exclusivity.
- Generic entry post-patent expiry leads to price reductions but also fosters investments in advanced drug delivery technologies.
- Regulatory pathways favor drugs that demonstrate improved safety, efficacy, or adherence.
- Market growth is driven by increasing alcohol consumption and unmet needs for more effective treatments.
FAQs
1. Which drugs in ATC Class N07BB are closest to patent expiration?
Acamprosate patents are set to expire around 2024–2025, with generic versions expected to enter the market immediately afterward.
2. What are the barriers to patenting new N07BB drugs?
Challenges include demonstrating significant improvement over existing therapies, navigating complex regulatory standards, and facing patent invalidation risks, especially concerning formulation patents.
3. Are there breakthroughs in drug delivery systems for alcohol dependence?
Yes. Recent patents focus on long-acting injectable forms, transdermal patches, and implantable devices that improve adherence and reduce dosing frequency.
4. How do regional patent laws impact market competition?
Patent protection varies by jurisdiction, with some countries allowing patent challenges that reduce exclusivity periods, affecting global market dynamics.
5. What is the outlook for new entrants in this space?
Innovation in delivery systems and combination therapies presents opportunities, particularly if new formulations demonstrate superior adherence, safety, or efficacy.
References
[1] MarketWatch. (2022). Alcohol dependence treatment market size, share, trends, forecast. Retrieved from https://www.marketwatch.com
More… ↓
